AntriaBio Announces First Patient Dosed in Clinical Study

Pharmaceutical Investing

AntriaBio announced the dosing of the first patient in their Phase 1 first-in-human clinical trial of its lead product candidate, AB101.

AntriaBio (OTCQB:ANTB) announced the dosing of the first patient in their Phase 1 first-in-human clinical trial of its lead product candidate, AB101.
As quoted in the press release:

“The successful filing of the IND followed by initiation of the first-in-human clinical trial for AB101 are significant milestones for our Company as these events validate our robust preclinical results and bring us to the doorstep of being able to demonstrate clinical proof-of-concept for AB101 as a once-weekly insulin,” stated Brian Roberts, M.D., Vice President of Clinical Development at AntriaBio. “Based on animal data, AB101 has the potential to improve overall glycemic control in patients with diabetes while offering a more convenient injection regimen compared to currently available basal insulins. The availability of such a therapy could optimize initiation and adherence to insulin and provide an important treatment option for patients and providers at a time when diabetes continues to increase to historic proportions.”
The Phase 1 clinical trial is a first-in-human single ascending dose study to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of AB101 in patients with type 1 diabetes mellitus.

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
×